Antibody Therapy Market Source, By Type (Murine, Chimeric, Humanized, Human), By Type (In Vivo, In Vitro), By Use case (Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, Others), By End-use (Hospitals, Specialty Centers, Others), By Region - Global Analysis Forecast Till 2030

The Antibody Therapy Market was estimated at USD 195.50 billion in 2021, with a compound annual growth rate (CAGR) of 12.35% projected from 2022 to 2030.

Monoclonal antibodies (MABS) are proteins created in a lab to boost your immune system. Monoclonal antibody treatments are frequently given as IV solutions, usually in an infusion centre. Antibodies are a type of immune system component. They seek out and adhere to antigens (foreign substances) to kill them.

The most common sources are murine, chimeric, humanized, and human monoclonal antibodies (MABS). A murine antibody contains two types of chains, one from a mouse and one from a human. The pre-stem -o- in a murine antibody's INN is used to identify it. It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular, cerebrovascular, and other applications in hospitals, private clinics, and research institutes.

Market Dynamics

Drivers:

Increasing regulatory approvals and the introduction of new therapies are propelling the market forward.

The increased approval of monoclonal antibodies by regulatory offices encourages the development of novel therapeutics, which is expected to drive market growth over the forecast period. For example, in 2018, Chugai Pharmaceutical Co., Ltd. (part of Roche Holding AG) announced that its product, Satralizumab, had received Breakthrough Therapy Designation from the US FDA. Darzalex (daratumumab) was approved by the US Food and Drug Administration in May 2018 in combination with Velcade (bortezomib), melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant (ASCT).

Increased costs and stringent regulatory measures are likely to stymie market growth.

Higher costs and stringent regulatory measures, which result in lengthy approval procedures, may limit the Antibody Therapy market growth. The advantage of drugs derived from mAbs is that they are highly specific and have limited targets. This is because they associate with cells but do not penetrate them. Another issue with using mAbs is that, unlike small molecule drugs, they must be injected.

Restraints:

Despite promising results for monoclonal antibodies in treating various diseases, the lengthy and stringent approval and launch procedures will greatly impede monoclonal antibody therapy revenue. Many clinical studies are withdrawn, primarily due to failure to meet the regulatory government’s strict regulations and end results. In addition, the potential side effects of these drugs are another factor limiting the growth of the antibody therapy market.

Key players:

• Novartis AG

• Pfizer Inc

• GlaxoSmithKline plc

• Amgen Inc.

• Merck & Co., Inc.

• Daiichi Sankyo Company, Limited

• Abbott Laboratories

• AstraZeneca plc

• Eli Lilly And Company

• Johnson & Johnson Services, Inc.

• Bayer AG

• Bristol Myers Squibb

• F. Hoffman-La Roche Ltd.

• Viatris Inc.

• Biogen Inc.

• Thermo Fisher Scientific, Inc.

Market Segmentation:

Antibody Therapy Market, By Source type,

• Murine

• Chimeric

• Humanized

• Human

Antibody Therapy Market, By Production Type,

• In Vivo

• In Vitro

Antibody Therapy Market, By Application,

• Oncology

• Autoimmune Diseases

• Infectious Diseases

• Neurological Diseases

• Others

Antibody Therapy Market, By End-use,

• Hospitals

• Specialty Centers

• Others

Antibody Therapy Market, By Region

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East & Africa

Regional Analysis:

North America held the largest market share of XX% in 2021, owing to well-developed healthcare infrastructure, high patient awareness, and increased cancer research prospects, among other factors. Furthermore, rising government spending on cancer research and key players such as Pfizer Inc., Amgen, Inc., and Merck & Co. are expected to drive antibody therapy market growth.

Due to rising disposable income with the large patient pool for mAb cancer therapeutics, and a growing focus on healthcare, the Asia Pacific region is expected to grow at the fastest rate during the forecast period. Countries such as India and China provide appealing investment opportunities for clinical research and are expected to boost mAb research and development prospects.

Scope of the Report:

User

Tab Content